Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRV NASDAQ:ADAP NASDAQ:CALC NASDAQ:EGRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.65-7.8%$1.34$1.05▼$10.00$56.31M1.663.12 million shs3.39 million shsADAPAdaptimmune Therapeutics$0.05+15.8%$0.14$0.04▼$1.17$11.27M2.2459.70 million shs26.26 million shsCALCCalciMedica$3.58+15.9%$2.79$1.42▼$5.65$43.17M1.3253,735 shs59,111 shsEGRXEagle Pharmaceuticals$3.21+5.9%$3.32$1.50▼$3.87$41.69M0.836,260 shs866 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics-7.82%+23.13%+33.06%+29.92%-79.11%ADAPAdaptimmune Therapeutics+15.76%-14.88%-36.52%-81.93%-95.57%CALCCalciMedica+15.86%+15.48%+30.66%+97.79%-27.75%EGRXEagle Pharmaceuticals0.00%+3.72%+0.63%+39.57%-17.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.65-7.8%$1.34$1.05▼$10.00$56.31M1.663.12 million shs3.39 million shsADAPAdaptimmune Therapeutics$0.05+15.8%$0.14$0.04▼$1.17$11.27M2.2459.70 million shs26.26 million shsCALCCalciMedica$3.58+15.9%$2.79$1.42▼$5.65$43.17M1.3253,735 shs59,111 shsEGRXEagle Pharmaceuticals$3.21+5.9%$3.32$1.50▼$3.87$41.69M0.836,260 shs866 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics-7.82%+23.13%+33.06%+29.92%-79.11%ADAPAdaptimmune Therapeutics+15.76%-14.88%-36.52%-81.93%-95.57%CALCCalciMedica+15.86%+15.48%+30.66%+97.79%-27.75%EGRXEagle Pharmaceuticals0.00%+3.72%+0.63%+39.57%-17.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 3.00Buy$15.50839.39% UpsideADAPAdaptimmune Therapeutics 2.00Hold$1.352,647.29% UpsideCALCCalciMedica 3.00Buy$16.00346.93% UpsideEGRXEagle Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ADAP, CALC, ACRV, and EGRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025ACRVAcrivon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $8.007/29/2025ADAPAdaptimmune TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/29/2025ADAPAdaptimmune TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral6/26/2025ADAPAdaptimmune TherapeuticsMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Neutral$1.50 ➝ $0.50(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.68 per shareN/AADAPAdaptimmune Therapeutics$178.03M0.07N/AN/A$0.05 per share0.98CALCCalciMedicaN/AN/AN/AN/A$1.07 per shareN/AEGRXEagle Pharmaceuticals$257.55M0.16$8.03 per share0.40N/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$80.56M-$2.25N/AN/AN/AN/A-50.78%-46.08%11/12/2025 (Estimated)ADAPAdaptimmune Therapeutics-$70.81M-$0.65N/AN/AN/A-260.82%-163.73%-75.83%11/12/2025 (Estimated)CALCCalciMedica-$13.70M-$1.60N/AN/AN/AN/A-206.51%-103.81%11/12/2025 (Estimated)EGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/ALatest ADAP, CALC, ACRV, and EGRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ACRVAcrivon Therapeutics-$0.57-$0.55+$0.02-$0.55N/AN/A8/13/2025Q2 2025ADAPAdaptimmune Therapeutics-$0.15-$0.11+$0.04-$0.11$11.04 million$13.68 million8/12/2025Q2 2025CALCCalciMedica-$0.40-$0.40N/A-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/AADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/ACALCCalciMedicaN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A10.3110.31ADAPAdaptimmune Therapeutics4.241.521.29CALCCalciMedica1.395.455.45EGRXEagle PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%ADAPAdaptimmune Therapeutics31.37%CALCCalciMedicaN/AEGRXEagle Pharmaceuticals85.36%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics8.50%ADAPAdaptimmune Therapeutics12.44%CALCCalciMedica41.55%EGRXEagle Pharmaceuticals28.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.46 million28.78 millionNot OptionableADAPAdaptimmune Therapeutics490265.05 million232.08 millionOptionableCALCCalciMedica3013.97 million8.17 millionNo DataEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataADAP, CALC, ACRV, and EGRX HeadlinesRecent News About These CompaniesEagle Pharmaceuticals to Appoint Abhinav Jain to its Board of DirectorsAugust 28, 2025 | globenewswire.comEagle Pharmaceuticals Announces 2025 Annual Meeting DateAugust 18, 2025 | globenewswire.comEagle Pharmaceuticals, Inc. (EGRX) - Yahoo FinanceJuly 10, 2025 | finance.yahoo.comEGRX Eagle Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comEagle Pharmaceuticals Insider Trading Activity | OTC:EGRX | BenzingaApril 28, 2025 | benzinga.comEagle Pharmaceuticals announces $69M pact to monetize Bendeka royaltiesApril 1, 2025 | markets.businessinsider.comEagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® RoyaltiesMarch 31, 2025 | markets.businessinsider.comEagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights PlanMarch 21, 2025 | globenewswire.comEagle Pharma Founder Sues Company to Recoup Cost of SEC InvestigationNovember 23, 2024 | law.comLEagle Pharmaceuticals to Delist from NasdaqNovember 18, 2024 | investing.comEagle Announces Update on Delisting from Nasdaq and SEC DeregistrationNovember 15, 2024 | globenewswire.comEagle Pharmaceuticals Appoints New CFO Amid Leadership ChangeNovember 12, 2024 | markets.businessinsider.comEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanNovember 1, 2024 | finanznachrichten.deEagle Pharmaceuticals Implements Stockholder Rights PlanNovember 1, 2024 | markets.businessinsider.comEagle Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanOctober 31, 2024 | markets.businessinsider.comUnion Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals SharesOctober 8, 2024 | gurufocus.comWhy Did Eagle Pharmaceuticals Inc (EGRX) Stock Plunge -77.22% Last Week?October 7, 2024 | bovnews.comBEagle Pharmaceuticals (NASDAQ:EGRX) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comEagle Pharmaceuticals IncSeptember 28, 2024 | money.usnews.comIs Eagle Materials Inc. (EXP) the Best Stock Pick You Need to Know in Jim Cramer’s Latest Watchlist?September 15, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025ADAP, CALC, ACRV, and EGRX Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.65 -0.14 (-7.82%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$1.61 -0.04 (-2.42%) As of 09/9/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Adaptimmune Therapeutics NASDAQ:ADAP$0.05 +0.01 (+15.76%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$0.05 +0.00 (+0.41%) As of 09/9/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.CalciMedica NASDAQ:CALC$3.58 +0.49 (+15.86%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$3.54 -0.04 (-0.98%) As of 09/9/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Eagle Pharmaceuticals NASDAQ:EGRX$3.21 +0.18 (+5.94%) As of 09/8/2025 03:29 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
